Petr Kavan

12.5k total citations · 1 hit paper
141 papers, 4.4k citations indexed

About

Petr Kavan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Petr Kavan has authored 141 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 28 papers in Cancer Research. Recurrent topics in Petr Kavan's work include Colorectal Cancer Treatments and Studies (52 papers), Cancer Treatment and Pharmacology (26 papers) and Glioma Diagnosis and Treatment (25 papers). Petr Kavan is often cited by papers focused on Colorectal Cancer Treatments and Studies (52 papers), Cancer Treatment and Pharmacology (26 papers) and Glioma Diagnosis and Treatment (25 papers). Petr Kavan collaborates with scholars based in Canada, United States and France. Petr Kavan's co-authors include Warren Mason, Timothy F. Cloughesy, Wolfgang Wick, Khê Hoang‐Xuan, Ryo Nishikawa, Magalie Hilton, Alain Carpentier, Roger Henriksson, Olivier Chinot and Dana Cernea and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Petr Kavan

131 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

2014 1.8k citations Olivier Chinot, Wolfgang Wick et al. profile →

Peers

Countries citing papers authored by Petr Kavan

Since Specialization

Citations

This map shows the geographic impact of Petr Kavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petr Kavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petr Kavan more than expected).

Fields of papers citing papers by Petr Kavan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petr Kavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petr Kavan. The network helps show where Petr Kavan may publish in the future.

Co-authorship network of co-authors of Petr Kavan

This figure shows the co-authorship network connecting the top 25 collaborators of Petr Kavan. A scholar is included among the top collaborators of Petr Kavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petr Kavan. Petr Kavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis 2025 ·Current Oncology ·Matthew Dankner, (unknown), Mark Sorin, (unknown), (unknown), (unknown), Jamie Magrill, (unknown), Joan Miguel Romero, Gerald Batist, Petr Kavan, April A. N. Rose, (unknown)	0
2	44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy 2024 ·Annals of Oncology ·Grainne M. O’Kane, Jennifer L. Spratlin, D-Y. Oh, Sun Young Rha, Elaine McWhirter, (unknown), Petr Kavan, (unknown), (unknown), Rachel Goodwin, J. Randolph Hecht, (unknown), (unknown), (unknown), Michelle Jones, (unknown), (unknown), Gonzalo Spera, (unknown)	1
3	Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D 2024 ·Clinical Colorectal Cancer ·Richard D. Kim, Mustapha Tehfé, Petr Kavan, Jorge Chaves, Jeremy Kortmansky, Eric X. Chen, Christopher H. Lieu, Lucas Wong, Marwan Fakih, Kristen Spencer, Qing Zhao, (unknown), (unknown), Pierre Leconte, David E. Adelberg, E. Gabriela Chiorean	8
4	A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001). 2024 ·Journal of Clinical Oncology ·Grainne M. O’Kane, Do‐Youn Oh, Jennifer L. Spratlin, Sun Young Rha, Elena Elimova, Petr Kavan, Rachel Goodwin, Yongjun Cha, Seung Tae Kim, (unknown), Michelle Jones, (unknown), (unknown), Gonzalo Spera, (unknown)	2
5	The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers 2024 ·Cancers ·(unknown), (unknown), Matthew Dankner, David W. Cescon, Anna Spreafico, (unknown), Petr Kavan, Gerald Batist, April A. N. Rose	7
6	Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E 2024 ·Clinical Colorectal Cancer ·Eric X. Chen, Petr Kavan, Mustapha Tehfé, Jeremy Kortmansky, Michael B. Sawyer, E. Gabriela Chiorean, Christopher H. Lieu, Blasé N. Polite, Lucas Wong, Marwan Fakih, Kristen Spencer, Jorge Chaves, (unknown), Pierre Leconte, David E. Adelberg, Richard D. Kim	2
7	A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy 2023 ·International Journal of Molecular Sciences ·Karen Gambaro, Maud Marques, (unknown), (unknown), Cyrla Hoffert, Archana Srivastava, (unknown), Thierry Alcindor, Adrian Langleben, Lucas Sidéris, Mahmoud Abdelsalam, Mustapha Tehfé, Félix Couture, Gerald Batist, Petr Kavan	0
8	Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164 2023 ·European Journal of Cancer ·Dung T. Le, Luis A. Díaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André	46
9	Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus 2021 ·Current Oncology ·Marc Carrier, Normand Blais, Mark Crowther, Petr Kavan, Grégoire Le Gal, Otto Moodley, Sudeep Shivakumar, Deepa Suryanarayan, Vicky Tagalakis, Cynthia Wu, Agnes Lee	31
10	Cancer!? I Don't Have Time for That: Impact of a Psychosocial Intervention for Young Adults with Cancer 2018 ·Journal of Adolescent and Young Adult Oncology ·Sylvie Aubin, Zeev Rosberger, (unknown), (unknown), Samara Perez, Sonja Lehmann, Gerald Batist, Petr Kavan	9
11	Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study 2017 ·Clinical Colorectal Cancer ·Young Soo Rho, Marine Gilabert, Karol Połom, (unknown), Kateřina Kopečková, (unknown), Niamh Coleman, Megan Greally, Daniele Marrelli, Franco Roviello, Ray McDermott, (unknown), (unknown), Zbyněk Bortlíček, Jana Prausová, Gerald Batist, Laurent Azoulay, Petr Kavan	54
12	Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas 2016 ·Oncology ·Marine Gilabert, Young Soo Rho, Petr Kavan	10
13	Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment 2015 ·Current Oncology ·Jacob C. Easaw, Melissa Shea‐Budgell, Chengliang Wu, Piotr Czaykowski, Jeannine Kassis, (unknown), (unknown), Mary MacNeil, (unknown), (unknown), (unknown), Otto Moodley, Sudeep Shivakumar, Vicky Tagalakis, S. Welch, Petr Kavan	38
14	High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial 2015 ·PLoS ONE ·L. John Hoffer, Line Robitaille, Robert Zakarian, David Melnychuk, Petr Kavan, Jason Agulnik, Victor Cohen, David Small, Wilson H. Miller	88
15	Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer 2015 ·Clinical Colorectal Cancer ·(unknown), Young Soo Rho, (unknown), Aline Mamo, Marine Gilabert, (unknown), Lawrence Panasci, David Melnychuk, Gerald Batist, Petr Kavan	27
16	An Indirect Treatment Comparison and Cost-Effectiveness Analysis Comparing Folfirinox with Nab-Paclitaxel Plus Gemcitabine for First-Line Treatment for Patients with Metastatic Pancreatic Cancer 2014 ·Annals of Oncology ·(unknown), (unknown), (unknown), Petr Kavan	5
17	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma 2014 ·Neuro-Oncology ·David A. Reardon, Burt Nabors, Warren Mason, James Perry, William Shapiro, Petr Kavan, David Mathieu, Surasak Phuphanich, A. Cseh, Yan Fu, Cong Jiang, Sven Wind, David D. Eisenstat	134
18	FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA 2013 ·Neuro-Oncology ·Olivier Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Alain Carpentier, Khê Hoang‐Xuan, Petr Kavan, Dana Cernea, Alba A. Brandes, Magalie Hilton, Yannick Kerloëguen, (unknown), (unknown)	3
19	Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study 2010 ·Journal of Clinical Oncology ·James Perry, Karl Bélanger, Warren Mason, Dorcas Fulton, Petr Kavan, Jacob C. Easaw, (unknown), Sarah Kirby, David Macdonald, David D. Eisenstat, Brian Thiessen, Peter Forsyth, Jean‐François Pouliot	264
20	Canadian Association of Neuropathologists 2008 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·(unknown), (unknown), (unknown), David Roberge, Petr Kavan, Luís Souhami, Lili‐Naz Hazrati, A Brown, (unknown), Eric Monsalves, Uri Tabori, Cynthia Hawkins	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact